Cresilon’s Traumagel is the first gel-based hemostatic agent to be cleared by the US Food and Drug Administration for use in patients with moderate to severe bleeding.
The company’s CEO, Joe Landolina, who invented the technology at age 17 as a college student at New York University, told Medtech Insight that compared with many available products like gauzes, powders, and sponges to stop bleeding,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?